Johnson & Johnson Co. (JNJ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joaquin Duato
Employees:
141,700
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ 08933
732-524-2455

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands. Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis. MedTech segment provides electrophysiology products to treat cardiovascular diseases.

Data derived from most recent annual or quarterly report
Market Cap 439.812 Billion Shares Outstanding2.631 Billion Avg 30-day Volume 6.072 Million
P/E Ratio26.0776 Dividend Yield2.4008 EPS1.35
Price to Revenue5.0105 Debt to Equity0.4269 EBITDA27.573 Billion
Price to Book Value6.2724 Operating Margin23.4684 Enterprise Value478.97 Billion
Current Ratio1.425 EPS Growth0.033 Quick Ratio1.087
1 Yr BETA 0.2785 52-week High/Low 185.5 / 153.87 Profit Margin19.2137
Operating Cash Flow Growth-9.6959 Altman Z-Score4.8743 Free Cash Flow to Firm 21.58 Billion
Earnings Report2022-10-18
View SEC Filings from JNJ instead.

View recent insider trading info

Johnson & Johnson Co. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding JNJ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding JNJ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-14 by WENGEL KATHRYN E
  • 4: filed on 2022-06-09 by WEINBERGER MARK A
  • 4: filed on 2022-06-09 by WASHINGTON A. EUGENE
  • 4: filed on 2022-06-09 by HEWSON MARILLYN A
  • 4: filed on 2022-05-31 by DECKER ROBERT J
  • 4: filed on 2022-04-25 by HAIT WILLIAM
  • 4: filed on 2022-03-21 by MONGON THIBAUT
  • 4: filed on 2022-03-21 by MONGON THIBAUT
  • 4: filed on 2022-03-17 by DECKER ROBERT J
  • 4: filed on 2022-03-09 by WASHINGTON A. EUGENE

    • Events (8k)

  • 8-K: filed on 2022-07-19:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-19:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-15:
    Item 8.01: Other Events
  • 8-K: filed on 2021-10-19:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WENGEL KATHRYN E EVP, CHIEF GSC OFFICER

    • Officer
    		 88,052 2022-06-10 3

    HEWSON MARILLYN A

    • Director
    		 5,652 2022-06-07 5

    WASHINGTON A. EUGENE

    • Director
    		 27,433 2022-06-07 5

    WEINBERGER MARK A

    • Director
    		 5,774 2022-06-07 5

    DECKER ROBERT J CONTROLLER, CAO

    • Officer
    		 16,169 2022-05-26 5

    HAIT WILLIAM SEE REMARKS

    • Officer
    		 109,934 2022-04-21 5

    MONGON THIBAUT EXEC VP, WW CHAIR, CONSUMER

    • Officer
    		 70,824 2022-03-17 4

    WILLIAMS RONALD A

    • Director
    		 25,673 2022-02-15 1

    MULCAHY ANNE M

    • Director
    		 17,706 2022-02-15 1

    PRINCE CHARLES

    • Director
    		 24,824 2022-02-15 1

    DAVIS D SCOTT

    • Director
    		 12,197 2022-02-15 1

    JOLY HUBERT

    • Director
    		 3,614 2022-02-15 1

    DAVIS IAN

    • Director
    		 17,706 2022-02-15 1

    BECKERLE MARY C

    • Director
    		 10,355 2022-02-15 1

    MCCLELLAN MARK B.

    • Director
    		 14,323 2022-02-15 1

    ADAMCZYK DARIUS

    • Director
    		 1,030 2022-02-15 2

    DOUDNA JENNIFER A

    • Director
    		 5,133 2022-02-15 1

    WEST NADJA

    • Director
    		 2,327 2022-02-15 1

    MAMMEN MATHAI EVP, PHARM, R&D

    • Officer
    		 85,329 2022-02-14 3

    GORSKY ALEX

    • Director
    		 822,226 2022-02-14 3

    FASOLO PETER EXEC VP, CHIEF HR OFFICER

    • Officer
    		 279,682 2022-02-14 2

    ULLMANN MICHAEL H EXEC VP, GENERAL COUNSEL

    • Officer
    		 153,578 2022-02-14 2

    DUATO JOAQUIN CEO

    • Officer
    • Director
    		 354,457 2022-02-14 3

    WOLK JOSEPH J EXEC VP, CFO

    • Officer
    		 27,322 2022-02-14 2

    MCEVOY ASHLEY EVP, WW CHAIR, MEDICAL DEVICES

    • Officer
    		 115,683 2022-02-14 2

    TAUBERT JENNIFER L EVP, WW CHAIR, PHARMACEUTICALS

    • Officer
    		 212,285 2022-02-14 2

    BROADHURST VANESSA EVP, GLOBAL CORP AFF.

    • Officer
    		 35,818 2022-02-14 3

    SWANSON JAMES D. EVP, CHIEF INFORMATION OFFICER

    • Officer
    		 1,084 2022-01-03 1

    STOFFELS PAULUS VICE CHAIR, EXEC COMMITTEE

    • Officer
    		 275,547 2021-02-12 0

    SNEED MICHAEL E EVP, GLOBAL CORP AFF & CCO

    • Officer
    		 66,060 2021-02-12 0

    PEREZ WILLIAM D

    • Director
    		 16,030 2020-03-13 0

    MESQUITA JORGE S. EXEC VP, WW CHAIR, CONSUMER

    • Officer
    		 27,344 2019-02-08 0

    KAPUSTA RONALD A CONTROLLER, CAO

    • Officer
    		 18,522 2019-02-08 0

    PETERSON SANDRA E EXEC VP, GROUP WW CHAIRMAN

    • Officer
    		 83,349 2018-02-12 0

    CARUSO DOMINIC J EXEC VP, FINANCE; CFO

    • Officer
    		 171,986 2018-02-12 0

    PRUDEN GARY J EXEC VP, WW CHAIR, MED DEVICES

    • Officer
    		 43,726 2017-02-28 0

    LINDQUIST SUSAN L

    • Director
    		 0 2016-09-06 0

    COLEMAN MARY SUE

    • Director
    		 11,952 2016-02-08 0

    CULLEN JAMES

    • Director
    		 0 2015-02-09 0

    COSGROVE STEPHEN J CORPORATE CONTROLLER

    • Officer
    		 0 2015-02-09 0

    MULLIN LEO F

    • Director
    		 0 2015-02-09 0

    JOHNS MICHAEL M E

    • Director
    		 15,290 2014-02-10 0

    SATCHER DAVID

    • Director
    		 15,393 2013-02-11 0

    WELDON WILLIAM C

    • FORMER CHAIRMAN OF THE BOARD
    		 No longer subject to file 2013-02-08 0

    DEYO RUSSELL C VP, GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2012-02-22 0

    MCCOY SHERILYN S MEMBER, EXECUTIVE COMMITTEE

    • Officer
    		 81,370 2012-02-09 0

    GOGGINS COLLEEN A MEMBER, EXECUTIVE COMMITTEE

    • Officer
    		 109,043 2011-01-10 0

    LANGBO ARNOLD G

    • Director
    		 10,190 2010-03-09 0

    FOSTER-CHEEK KAYE I VP, HUMAN RESOURCES

    • Officer
    		 5,797 2009-12-31 0

    VALERIANI NICHOLAS J VP, STRATEGY & GROWTH

    • Officer
    • Director
    • MEMBER, EXECUTIVE COMMITTEE
    		 67,429 2009-09-30 0

    CASEY DONALD M JR. MEMBER, EXECUTIVE COMMITTEE

    • Officer
    		 44,960 2009-09-10 0

    POON CHRISTINE A VICE CHAIRMAN

    • Officer
    • Director
    		 55,889 2009-02-12 0

    SCODARI JOSEPH C

    • RETIRED EXEC COMMITTEE MEMBER
    		 No longer subject to file 2008-05-28 0

    REINEMUND STEVEN

    • Director
    		 7,713 2007-12-11 0

    JORDAN ANN DIBBLE

    • Director
    		 28,777 2007-03-13 0

    DARRETTA ROBERT J VICE CHAIRMAN

    • Officer
    • Director
    		 231,237 2007-02-16 0

    PETERSON PER A EXECUTIVE COMMITTEE MEMBER

    • Officer
    		 32,833 2007-02-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    JOHNSON & JOHNSON JNJ 2022-08-12 18:15:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 17:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 17:15:05 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 16:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 16:15:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 15:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 15:15:05 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 14:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 14:15:05 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 13:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 13:15:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-12 12:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 22:15:03 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 21:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 21:15:03 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 20:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 20:15:03 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 19:45:04 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 19:15:05 UTC 2.07 0.25 0
    JOHNSON & JOHNSON JNJ 2022-08-11 18:45:03 UTC 2.07 0.25 0

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Ultimus Managers Trust- WAYCROSS LONG/SHORT EQUITY FUND JNJ -5300.0 shares, $-813073.0 2020-08-31 N-PORT
    JPMorgan Trust I- JPMorgan Research Market Neutral Fund JNJ -3165.0 shares, $-571155.9 2022-04-30 N-PORT
    Waycross Independent Trust- WAYCROSS LONG/SHORT EQUITY FUND JNJ -6300.0 shares, $-1131039.0 2022-05-31 N-PORT

    Elevate your investments